^
Association details:
| Biomarker: | ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Hormone Receptor–Positive Breast Cancer Sensitive to Pembrolizumab: Evidence of the Pathogenicity of the MLH1 Variant 1835del3
Published date:
08/29/2023
Excerpt:
A woman with estrogen/progesterone receptor-positive, ERBB2-negative metastatic breast cancer...Because of the finding of MSI-H and a high TMB in tumor tissue along with the presence of an MLH1 variant that might be pathogenic, she received 4 doses of pembrolizumab postoperatively, resulting in a spectacular complete remission of her disease.
DOI:
https://doi.org/10.6004/jnccn.2023.7035
